Development and Validation of Atazanavir and Ritonavir Determination in Human Plasma by HPLC-MS Method

Introduction. HIV infection is one of the most relevant diseases from a medical, epidemiological and social point of view. Timely diagnosis, detection and control of the disease, adequate prescription of antiretroviral therapy can sufficiently reduce the viral load on the patient's body, reduce the risk of transmission of infection. Currently, combinations of various antiretroviral drugs are increasingly being prescribed as therapy. One of the most important is combination of atazanavir and ritonavir. The most important stage for the study of pharmacokinetics, studies of comparative pharmacokinetics and bioequivalence is the development of an analytical method that allows you to determine the investigated substances in human plasma. There are currently no published methods for the determination of atazanavir and ritonavir in human plasma using high performance liquid chromatography with mass selective detection using a single quadrupole mass detector. In this article presents the development and validation of a method for the determination of atazanavir and ritonavir in blood plasma after sample preparation by the method of protein precipitation.

Aim. The aim of the study is to develop a method for the quantitative determination of atazanavir and ritonavir in human plasma by HPLC with mass spectrometric detection for performing the analytical part of pharmacokinetic studies.

Materials and methods. Determination of atazanavir and ritonavir in human plasma by HPLC with mass spectrometric detection. A sample was prepared using protein deposition.

Results and discussion. The method was validated of selectivity, matrix effect, calibration curve, accuracy, precision, limit of quantification, carry-over effect and sample stability.

Conclusion. The method of the determination of atazanavir and ritonavir in human plasma was developed and validated by HPLC-MS. The analytical range of the was 50.0–10000.0 ng/mL in plasma for atazanavir and 10.0–2500.0 ng/mL in plasma for ritonavir. Method could be applied to determination of atazanavir and ritonavir in plasma for PK and BE studies.

1. Zaitseva N. N., Efimov E. I., Solntsev L. A. Electronic Atlas in HIV Surveillance. Medical almanac. 2014; 4(34): 63–67 (in Russ.).

2. The epidemiological situation of HIV infection in Russia. Available at: http://www.cgemo.ru/doks/news/epid-vich-2017.pdf (in Russ.).

3. Oleinik A. F., Fazylov V. Kh. Antiretroviral therapy as a method of preventing HIV infection. Infectious diseases: news, opinion, education. 2016; 3(6): 113–117 (in Russ.).

4. Severe P., Juste M. A. J, Ambroise A., Eliacin L., Marchand C., Apollon S., Edwards A., Bang H., Nicotera J., Godfrey C., Gulick R. M., Johnson W. D., Pape J. W., Fitzgerald D. W. Early versus standard antiretroviral therapy for HIV-infected adults in Haiti. New England Journal of Medicine. 2010; 3(363): 257–265. DOI: 10.1056/NEJMoa0910370.

5. Kravchenko A. V. Safety and efficacy of atazanavir as part of modern ART regimens. Far Eastern Journal of Infectious Pathology. 2010; 17: 220–235 (in Russ.).

6. Guaraldi G., Cocchi S., Motta A., Ciaffi S., Codeluppi M., Bonora S., Benedetto F.D., Masetti M., Floridia M., Baroncelli S., Pinetti D., D’Avolio A., Bertolini A., Esposito R. A pilot study on the efficacy, pharmacokinetics and safety of atazanavir in patients with endstage liver disease. Journal of Antimicrobial Chemotherapy. 2008; 6(62): 1356–1364. DOI: 10.1093/jac/dkn383.

7. Wempe M. F., Anderson P. L. Atazanavir metabolism according to CYP3A5 status: an in vitro-in vivo assessment. Drug Metabolism and Disposition. 2011; 3(39): 522–527. DOI: 10.1124/dmd.110.036178.

8. Antivirals for HIV: Protease Inhibitors. Available at: http://medzai.net/substances/atazanavir.php (in Russ.).

9. Hull M. W., Montaner J. S. G. Ritonavir-boosted protease inhibitors in HIV therapy. Annals of medicine. 2011; 5(43): 375–388. DOI: 10.3109/07853890.2011.572905.

10. Busti A. J., Hall R. G., Margolis D. M. Atazanavir for the treatment of human immunodeficiency virus infection. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2004; 12(24): 1732–1747. DOI: 10.1592/phco.24.17.1732.52347.

11. Cateaua E., Tourniera N., Dupuisb A., Moalc G.L., Venisse N. Determination of atazanavir in human plasma using solid-phase extraction and high-performance liquid chromatography. Journal of pharmaceutical and biomedical analysis. 2005; 3-4(39): 791–795. DOI: 10.1016/j.jpba.2005.04.025.

12. Cattaneo D., Maggiolo F., Ripamonti D., Perico N. Determination of atazanavir in human plasma by high-performance liquid chromatography with UV detection. Journal of chromatographic science. 2008; 6(46): 485–489. DOI: 10.1093/chromsci/46.6.485.

13. Kushakova A. S., Nikitina D. A., Novikov A. V. Method for determining the concentration of atazanavir in human blood plasma by RPHPLC with UV detection. Analytical chromatography and capillary electrophoresis. Materials of the III All-Russian Conference; 2017 May 21–27, Krasnodar, Russia. Krasnodar: Kuban State University; 2017: 88 (in Russ.).

14. Reddy A. V. B., Jaafar J., Aris A. B., Majid Z. A., Umar K., Talib J., Madhavi G. Development and validation of a rapid ultra high performance liquid chromatography with tandem mass spectrometry method for the simultaneous determination of darunavir, ritonavir, and tenofovir in human plasma: Application to human pharmacokinetics. Journal of separation science. 2015; 15(38): 2580–2587. DOI: 10.1002/jssc.201500250.

15. Mishra T., Shrivastav P. S. Validation of simultaneous quantitative method of HIV protease inhibitors atazanavir, darunavir and ritonavir in human plasma by UPLC-MS/MS. The Scientific World Journal. 2014. DOI: 10.1155/2014/482693.

16. Mironov A.N. Guidelines for the examination of medicines. T. II. M.: Grif and K. 2013: 280 (in Russ.).

17. Food and Drug Administration. Available at: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/bioanalytical-method-validation-guidance-industry.

18. European Medicines Agency. Available at: https://www.ema.europa.eu/en/bioanalytical-method-validation.

19. Reyataz. Available at: https://packageinserts.bms.com/pi/pi_reyataz.pdf.